Greater clarity regarding this transaction and future growth goals (without the Guidant acquisition) are needed.

Greater clarity regarding this transaction and future growth goals (without the Guidant acquisition) are needed,

The device replacements will cause companies to forgo revenue producing replacement units in future years.

Notable features - besides its overall clarity - are the naming of Iran and Syria, and his willingness to talk about a war against Islamic terror, not just generic 'terror.'

Overall, we found results in the quarter to be generally weak, but believe the strong market reaction was justified given the anticipated completion of the Guidant vascular acquisition.

Boston Scientific still has much 'wood to chop' regarding the recovery of the company's cardiac rhythm management business...That said, we believe earnings power for businesses remain substantial.